Table 1.
Variables for 3595 patients treated for renal cell carcinoma
| Stage, no. (%)* |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | Overall no. (%)* | I | II | III | IV | |||||
| Total | 3595 | (100.0) | 1915 | (53.3) | 388 | (10.8) | 895 | (24.9) | 397 | (11.0) |
| Age | ||||||||||
| Mean (median) | 62.8 | (67.0) | 62.9 | (68.0) | 61.9 | (59.0) | 63.1 | (63.0) | 62.7 | (61.0) |
| Range | 10–89 | 10–87 | 27–87 | 15–88 | 28–89 | |||||
| Sex | ||||||||||
| Male | 2397 | (66.7) | 1270 | (66.3) | 247 | (63.7) | 598 | (66.8) | 282 | (71.0) |
| Female | 1198 | (33.3) | 645 | (33.7) | 141 | (36.3) | 297 | (33.2) | 115 | (29.0) |
| Clinical stage | ||||||||||
| T1 | 1976 | (55.0) | 1915 | (100.0) | — | 19 | (2.1) | 42 | (10.6) | |
| T1a | 253 | (12.8) | 1129 | (59.0) | — | 5 | (0.5) | 11 | (2.3) | |
| T1b | 1723 | (87.2) | 786 | (41.9) | — | 14 | (1.6) | 31 | (8.3) | |
| T2 | 442 | (12.3) | — | 338 | (100.0) | 18 | (2.0) | 37 | (9.3) | |
| T3 | 1116 | (31.0) | — | — | 858 | (95.9) | 258 | (65.0) | ||
| T4 | 60 | (1.7) | — | — | — | 60 | (15.1) | |||
| Nodal metastases | ||||||||||
| N0 | 3334 | (92.7) | — | — | 768 | (85.8) | 263 | (66.2) | ||
| N1 | 234 | (6.5) | — | — | 127 | (14.2) | 107 | (27.0) | ||
| N2 | 27 | (0.8) | — | — | 0 | (0.0) | 27 | (6.8) | ||
| Metastases | ||||||||||
| M0 | 3240 | (90.1) | — | — | — | 42 | (10.6) | |||
| M1 | 355 | (9.9) | — | — | — | 355 | (89.4) | |||
| Tumour size, cm | ||||||||||
| Mean (median) | 6.2 | (5.2) | 4.0 | (4.0) | 9.8 | (9.0) | 7.8 | (7.5) | 9.3 | (9.0) |
| Range | 0.5–25 | 0.5–7 | 7.1–20 | 1.0–20 | 2.0–25 | |||||
| Fuhrman grade | ||||||||||
| I | 886 | (24.6) | 771 | (40.3) | 40 | (10.3) | 57 | (6.4) | 18 | (4.5) |
| II | 1470 | (40.9) | 860 | (44.9) | 230 | (59.3) | 300 | (33.5) | 80 | (20.2) |
| III | 1017 | (28.3) | 268 | (14.0) | 103 | (26.5) | 448 | (50.1) | 198 | (49.9) |
| IV | 222 | (6.2) | 16 | (0.8) | 15 | (3.9) | 90 | (10.1) | 101 | (25.4) |
| Histological type | ||||||||||
| Clear cell | 3168 | (88.1) | 1648 | (86.1) | 324 | (83.5) | 822 | (91.8) | 374 | (94.2) |
| Papillary | 326 | (9.1) | 211 | (11.0) | 41 | (10.6) | 52 | (5.8) | 22 | (5.5) |
| Chromophobe | 101 | (2.8) | 56 | (2.9) | 23 | (5.9) | 21 | (2.3) | 1 | (0.3) |
| Symptom classification | ||||||||||
| Asymptomatic | 2192 | (61.0) | 1506 | (78.6) | 183 | (47.2) | 408 | (45.6) | 95 | (23.9) |
| Local | 949 | (26.4) | 357 | (18.6) | 163 | (42.0) | 322 | (36.0) | 107 | (27.0) |
| Systemic | 454 | (12.6) | 52 | (2.7) | 42 | (10.8) | 165 | (18.4) | 195 | (49.1) |
| Follow-up, yr | ||||||||||
| Mean (median) | 4.0 | (2.9) | 3.8 | (2.8) | 4.6 | (4.0) | 4.2 | (3.0) | 4.2 | (2.8) |
| Range | 0.10–24.9 | 0.10–21.6 | 0.01–18.7 | 0.10–24.9 | 0.10–20.1 | |||||
*
Unless otherwise indicated.